1lxf: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="1lxf" size="450" color="white" frame="true" align="right" spinBox="true" caption="1lxf" /> '''Structure of the Regulatory N-domain of Hum...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1lxf.gif|left|200px]]<br />
[[Image:1lxf.gif|left|200px]]<br /><applet load="1lxf" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1lxf" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1lxf" />
caption="1lxf" />
'''Structure of the Regulatory N-domain of Human Cardiac Troponin C in Complex with Human Cardiac Troponin-I(147-163) and Bepridil'''<br />
'''Structure of the Regulatory N-domain of Human Cardiac Troponin C in Complex with Human Cardiac Troponin-I(147-163) and Bepridil'''<br />


==Overview==
==Overview==
Cardiac troponin C (cTnC) is the Ca(2+)-dependent switch for contraction, in heart muscle and a potential target for drugs in the therapy of heart, failure. Ca(2+) binding to the regulatory domain of cTnC (cNTnC) induces, little structural change but sets the stage for cTnI binding. A large, "closed" to "open" conformational transition occurs in the regulatory, domain upon binding cTnI(147-163) or bepridil. This raises the question of, whether cTnI(147-163) and bepridil compete for cNTnC.Ca(2+). In this work, we used two-dimensional (1)H,(15)N-heteronuclear single quantum coherence, (HSQC) NMR spectroscopy to examine the binding of bepridil to cNTnC.Ca(2+), in the absence and presence of cTnI(147-163) and of cTnI(147-163) to, cNTnC.Ca(2+) in the absence and presence of bepridil. The results show, that bepridil and cTnI(147-163) bind cNTnC.Ca(2+) simultaneously but with, negative cooperativity. The affinity of cTnI(147-163) for cNTnC.Ca(2+) is, reduced approximately 3.5-fold by bepridil and vice versa. Using, multinuclear and multidimensional NMR spectroscopy, we have determined the, structure of the cNTnC.Ca(2+).cTnI(147-163).bepridil ternary complex. The, structure reveals a binding site for cTnI(147-163) primarily located on, the A/B interhelical interface and a binding site for bepridil in the, hydrophobic pocket of cNTnC.Ca(2+). In the structure, the N terminus of, the peptide clashes with part of the bepridil molecule, which explains the, negative cooperativity between cTnI(147-163) and bepridil for, cNTnC.Ca(2+). This structure provides insights into the features that are, important for the design of cTnC-specific cardiotonic drugs, which may be, used to modulate the Ca(2+) sensitivity of the myofilaments in heart, muscle contraction.
Cardiac troponin C (cTnC) is the Ca(2+)-dependent switch for contraction in heart muscle and a potential target for drugs in the therapy of heart failure. Ca(2+) binding to the regulatory domain of cTnC (cNTnC) induces little structural change but sets the stage for cTnI binding. A large "closed" to "open" conformational transition occurs in the regulatory domain upon binding cTnI(147-163) or bepridil. This raises the question of whether cTnI(147-163) and bepridil compete for cNTnC.Ca(2+). In this work, we used two-dimensional (1)H,(15)N-heteronuclear single quantum coherence (HSQC) NMR spectroscopy to examine the binding of bepridil to cNTnC.Ca(2+) in the absence and presence of cTnI(147-163) and of cTnI(147-163) to cNTnC.Ca(2+) in the absence and presence of bepridil. The results show that bepridil and cTnI(147-163) bind cNTnC.Ca(2+) simultaneously but with negative cooperativity. The affinity of cTnI(147-163) for cNTnC.Ca(2+) is reduced approximately 3.5-fold by bepridil and vice versa. Using multinuclear and multidimensional NMR spectroscopy, we have determined the structure of the cNTnC.Ca(2+).cTnI(147-163).bepridil ternary complex. The structure reveals a binding site for cTnI(147-163) primarily located on the A/B interhelical interface and a binding site for bepridil in the hydrophobic pocket of cNTnC.Ca(2+). In the structure, the N terminus of the peptide clashes with part of the bepridil molecule, which explains the negative cooperativity between cTnI(147-163) and bepridil for cNTnC.Ca(2+). This structure provides insights into the features that are important for the design of cTnC-specific cardiotonic drugs, which may be used to modulate the Ca(2+) sensitivity of the myofilaments in heart muscle contraction.


==Disease==
==Disease==
Line 11: Line 10:


==About this Structure==
==About this Structure==
1LXF is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with CA and BEP as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1LXF OCA].  
1LXF is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=CA:'>CA</scene> and <scene name='pdbligand=BEP:'>BEP</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1LXF OCA].  


==Reference==
==Reference==
Line 17: Line 16:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Protein complex]]
[[Category: Protein complex]]
[[Category: Li, M.X.]]
[[Category: Li, M X.]]
[[Category: Sykes, B.D.]]
[[Category: Sykes, B D.]]
[[Category: Wang, X.]]
[[Category: Wang, X.]]
[[Category: BEP]]
[[Category: BEP]]
Line 27: Line 26:
[[Category: muscle]]
[[Category: muscle]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 18:04:54 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:49:21 2008''